Patents

Company receives third ISA247 patent

Published in Hepatitis Weekly, March 29th, 2004

Isotechnika, Inc., has received a notice of allowance for its U.S. patent application titled, "Deuterated Cyclosporine Analogs and their Use as Immunomodulating Agents."

This notice of allowance, in addition to patent numbers 6,605,593 and 6,613,739, pertains to Isotechnika's lead drug compound, ISA247. ISA247 is a novel immunosuppressive drug currently being investigated for the prevention of organ rejection in kidney transplant patients and in the treatment of psoriasis.

Joseph Koziak, executive vice president of Isotechnika, stated, "This notice of allowance represents the third patent approval for ISA247 in our primary market of the United States...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-03-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry